Blog Archives

Lemtrada: Deleterious unwanted effects in some multiple sclerosis patients

19 April 2019 – Alemtuzumab (Lemtrada) is used in the treatment of multiple sclerosis (MS). Moreover, Alemtuzumab, under the Tradenames of Campt, MabCampath and Campt-1H is on the markets for the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL),

Read more ›

Tags: , , , , , , , ,

Living theragenomic medicine: Direct to consumer test for metabolism of drugs FDA approved

November 08, 2018 –  The American Food and Drug Administration (FDA) has just authorized the first direct-to-consumer test for detecting genetic variants in genes that may govern the metabolism of drugs in individual patients.

Thus, FDA permits marketing, with special controls,

Read more ›

Tags: , , , , , , , , , , , , , , , ,

Lutetium 177 dotatate (Lutathera): A treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

January 29, 2018 – Gastroenteropancreatic neuroendocrine tumors (GEP-NET)s are a rare group of cancers with limited treatment options that affects primarily the pancreas or gastrointestinal tract of patients.  

The American Food &

Read more ›

Tags: , , , , , , ,

X-linked Hypophosphatemia: Burosumab (Crysvita) to the rescue

 December 16, 2017 – As recent as of December 14, 2017, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Burosumab (Crysvita),

Read more ›

Tags: , , , , , , , ,

Besponsa: Is this really a viable new treatment for ALL?

August 18, 2017 – B-cell precursor acute lymphoblastic leukemia (ALL) is a aggressive and rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. In the United States, the National Cancer Institute estimates that approximately 5,970 people will be diagnosed with B-cell ALL this year and approximately 1,440 will die from the disease.

Read more ›

Tags: , , , , , , , , , , ,

Rare diseases: EU and US collaborate to boost development of therapies

September 30, 2016 – This is very good news for patients suffering from any form of a rare disease. The European Medicines Agency (EMA) and the American Food and Drug Administration (FDA) have engaged in a joint effort to boost development of medicines for rare diseases.

Read more ›

Tags: , , , , ,

Palbociclib (Ibrance): New treatment for advanced or metastatic breast cancer in the EU

 September 17, 2016 – Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. In Europe, there were an estimated 464,000 new cases of breast cancer in 2012 and an estimated 131,000 deaths from the disease. Hormone receptor positive breast cancer accounts for 65% of tumours in women aged 35 to 65 years and 82% of tumours in women older than 65 years.

Read more ›

Tags: , , , , , , , , , , , , ,

Patient safety: EMA recommends suspension of medicines over flawed studies

August 08, 2016 –The following publication has just been released by the EMA. Because Thasso Post is not only about theragenomic and personalized medicine, but also about the safety of medicines for each individual patient, thasso feels that this is important information which highlights the degree of scrutiny applied by authorities in the quest to guarantee the quality and safety of approved medicines.

Read more ›

Tags: , , , ,

With Infliximab (Flixabi), a huge biosimilar medicine has been approved in the European Union (EU)

 June 22, 2016 – The European Medicines Agency (EMA) has approved, as of the end of May 2016, Infliximab (Flixabi). Infliximab (Flixabi) is a monoclonal antibody that has been designed to attach to a protein called tumour necrosis factor-alpha (TNF-alpha) and block its activity.

Read more ›

Tags: , , , , , , , , , , , ,

Are first-in-man (FIM) clinical trials unsafe?

June 01, 2016 – Are first-in-man (FIM) clinical trials unsafe? This question can certainly be answered with no, first-in-man (FIM) clinical trials (clinical Phase I studies) are generally not unsafe. In spite of this notion, and in the wake of the tragic incident which took place during a Phase I first-in-man (FIM) clinical trial in Rennes,

Read more ›

Tags: , , , , , , ,

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Genetically engineered animals offer fresh hope to heart valve patients December 6, 2019
    Scientists have cloned a genetically engineered bull which they hope will help heart valve transplant patients lead better quality lives and benefit people with red meat allergies.
  • 'Junk DNA' affects inherited cancer risk December 6, 2019
    A person's risk of developing cancer is affected by genetic variations in regions of DNA that don't code for proteins, previously dismissed as 'junk DNA', according to new research published in the British Journal of Cancer today.
  • Gene network sparks future autism treatment December 5, 2019
    A mutated gene found in people with intellectual disabilities that could be targeted for treatment has been identified by an international team including University of Queensland researchers.
  • Tick, tock: How stress speeds up your chromosomes' aging clock December 5, 2019
    Ageing is an inevitability for all living organisms, and although we still don't know exactly why our bodies gradually grow ever more decrepit, we are starting to grasp how it happens.
  • Genome testing for siblings of kids with autism may detect ASD before symptoms appear December 5, 2019
    One of the key priorities of interventions for autism spectrum disorder (ASD) is starting early, with some evidence showing infants as young as seven months old could benefit. Yet, most children in North America aren't diagnosed with ASD until they're over four years of age. New research led by The Hospital for Sick Children (SickKids) […]
Top